Neuracle Science Co., Ltd.

Company

Clinical-stage biotechnology company based in Seoul, South Korea, founded in 2015. Developer of NS101, an anti-FAM19A5 antibody in Phase 1b/2a trials for sudden sensorineural hearing loss as an early salvage therapy, not tinnitus.